Open access · US-GOV via ClinicalTrials.gov Clinical trial

Azacitidine in Combination With or Without All-trans Retinoic Acid in Newly Diagnosed Unfit Acute Myeloid Leukemia or Intermediate,High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria

Authors not listed

The First Affiliated Hospital of Soochow University · 2021

Deregulated nutrient-sensing Human Randomized controlled trial

Abstract

This is a randomized, open-label, multicenter study to compare the efficacy and safety of AZA with or without ATRA in newly diagnosed unfit AML or Intermediate,High or Very High Risk MDS

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-07-02 MST

Cite this

APA

Anonymous. (2021). Azacitidine in Combination With or Without All-trans Retinoic Acid in Newly Diagnosed Unfit Acute Myeloid Leukemia or Intermediate,High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria. <em>The First Affiliated Hospital of Soochow University</em>. https://clinicaltrials.gov/study/NCT05175508

Vancouver

Anonymous. Azacitidine in Combination With or Without All-trans Retinoic Acid in Newly Diagnosed Unfit Acute Myeloid Leukemia or Intermediate,High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria. The First Affiliated Hospital of Soochow University. 2021.

BibTeX

@misc{anon2021Azacit, title = {Azacitidine in Combination With or Without All-trans Retinoic Acid in Newly Diagnosed Unfit Acute Myeloid Leukemia or Intermediate,High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria}, author = {Anonymous}, journal = {The First Affiliated Hospital of Soochow University}, year = {2021}, }